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Background: Paraneoplastic retinopathy is caused by the cross-reaction of neoplasm-directed autoantibodies
against retinal antigens and results in retinal damage. Paraneoplastic vitelliform retinopathy, a presumed
paraneoplastic retinopathy with features of atypical melanoma-associated retinopathy, has recently been reported
in patients with metastatic melanoma. Ocular ultrastructure and its autoantibody localization of paraneoplastic
vitelliform retinopathy are still indefinable. This is the first report of anti-transient receptor potential M1 antibody
directly against human retinal bipolar dendritic tips in a melanoma patient with paraneoplastic vitelliform
retinopathy.
Case presentation: We present a pair of postmortem eyes of an 80-year-old male with metastatic cutaneous
melanoma, who developed paraneoplastic vitelliform retinopathy. The autopsied eyes were examined with light
microscopy, immunohistochemistry, and transmission electron microscopy. Microscopically, the inner nuclear layer
and outer plexiform layer were the most affected retinal structures, with local thinning. The lesions extended to the
outer nuclear layer, resulting in focal retinal degeneration, edema, and atrophy. No active inflammation or
melanoma cells were observed. Immunohistochemistry showed tightly compact bipolar cell nuclei (protein kinase C
alpha/calbindin positive) with blur/loss of ON bipolar cell dendritic tips (transient receptor potential M1 positive) in
diffusely condensed outer plexiform layer. The metastatic melanoma cells in his lung also showed immunoreactivity
against transient receptor potential M1 antibody. Transmission electron microscopy illustrated degenerated inner
nuclear layer with disintegration of cells and loss of cytoplasmic organelles. These cells contained many lysosomal
and autophagous bodies and damaged mitochondria. Their nuclei appeared pyknotic and fragmentary. The
synapses in the outer plexiform layer were extensively degenerated and replaced with empty vacuoles and
disintegrated organelles.
Conclusion: This case provides a convincing histological evidence of melanoma-associated autoantibodies directly
against transient receptor potential M1 channels that target the ON bipolar cell structures in the inner nuclear and
outer plexiform layers in paraneoplastic vitelliform retinopathy.
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Paraneoplastic retinopathy (PR) is mediated by tumor-
associated autoantibodies directed against retinal anti-
gens. PR patients usually develop reduced visual acuity,
photopsias, nyctalopia, visual field defects, and reduced
a- and/or b-waves in electroretinography (ERG) [1,2].
The two main types of PR are cancer-associated retinop-
athy (CAR) and melanoma-associated retinopathy
(MAR). CAR is mostly associated with small-cell lung
cancer and has specific autoantibodies against photore-
ceptors [3,4]. MAR typically develops in patients with
metastatic cutaneous or uveal melanoma; autoantibodies
against retinal bipolar cells are the hallmark of MAR
[5-8]. In MAR, the fundus is unremarkable in 44% cases,
although fundus changes such as focal depigmentation,
optic nerve pallor, and/or retinal vascular attenuation
have been reported [6,9]. Recently, a MAR-like retinop-
athy phenotype, termed paraneoplastic vitelliform retin-
opathy, has been recognized that is also associated with
cutaneous or uveal melanoma [10,11]. Unlike the typical
normal-appearing fundus in MAR, paraneoplastic vitelli-
form retinopathy is characterized by vitelliform retinal
lesions at the level of the retinal pigment epithelium
(RPE) with associated serous retinal detachment and sub-
retinal accumulation of hyperautofluorescent material in
the posterior pole [10,12].
Similar to CAR and MAR that are immunologically het-
erogeneous, serum autoantibodies, such as anti-bipolar
cell antigens, interphotoreceptor retinoid-binding protein
(IRBP), carbonic anhydrase II (CAII), and bestrophin, are
reported in patients with paraneoplastic vitelliform retin-
opathy [10,13,14]. Among them, anti-bipolar cell antibody
is the most commonly identified autoantibody [15,16]. As
reduced ERG b-wave is indicative of retinal bipolar cell
impairment, it is hypothesized that the autoantibodies
generated by melanoma patients are directed against ret-
inal bipolar cells in paraneoplastic vitelliform retinopathy.
Recently, a new connection between PR and bipolar
cells has been made by the identification of a cation chan-
nel named transient receptor potential M1 (TRPM1, also
known as melastatin 1). TRPM1 was initially identified in
melanocytes and cutaneous melanoma and is a marker for
metastasis and prognosis [17-19]. The loss or downregula-
tion of TRPM1 mRNA correlates with an increased risk of
metastatic melanoma [17,18]. The patterns of TRPM1
transcript expression also help differentiate Spitz nevi
from nodular melanomas, with higher ubiquitous expres-
sion in Spitz nevi and higher incidence of loss in nodular
melanomas [17]. TRPM1 is also expressed in retinal bipo-
lar dendritic tips [20-23]. Several studies demonstrated
that TRPM1 cation channel is essential for ON bipolar cell
signaling [22,24,25]. In addition, several groups have
found that human TRPM1 mutations are linked to con-
genital stationary night blindness [26-28]. Furthermore, ithas been reported that TRPM1 is the target of autoanti-
bodies in some PR patients [29,30].
As a subtype of PR, the exact pathogenesis of paraneo-
plastic vitelliform retinopathy remains elusive. Recently,
we reported the clinical manifestations and pathology of
a paraneoplastic vitelliform retinopathy case with lesions
in inner nuclear layer (INL), outer plexiform layer
(OPL), and outer nuclear layer (ONL) of the retina, the
loci of which correspond to the clinical fundus lesions
[16]. Herein, we re-examine this case including meta-
static melanoma cells in the lung with immunohisto-
chemistry and transmission electron microscopy (TEM).
Case presentation
Medical history
The detailed clinical history and some pathological find-
ings were described previously [16]. Briefly, an 80-year-
old male with lung biopsy confirmed metastatic melan-
oma was suspected of choroidal metastases. One year
after diagnosis with metastatic melanoma, he developed
nyctalopia and bilateral retinal lesions. The patient was
referred to the Department of Ophthalmic Oncology at
the Cole Eye Institute. His best corrected visual acuity
was 20/30 in the right eye and 20/25 in the left eye.
Fundus examination showed bilateral, multiple, deep,
yellowish lesions in the posterior pole and mid-
periphery. Optical coherence tomography excluded the
possibility of choroidal metastases. ERG showed a mild
reduction in both a- and b-wave amplitudes for both
scotopic and photopic waveforms. His serum was found
to have autoantibodies against CAII and an unknown
35-kDa RPE protein. The patient expired approximately
one month following ophthalmic examination.
Pathological findings
Gross examination showed two round, yellowish-white
deep retinal lesions barely visualized along the inferior
arcade temporal to the macula of the left eye [16].
Microscopically, focal edema, separation, and atrophy
were observed in the INL, extending to the OPL and
ONL (Figure 1). Neither active inflammatory infiltrates
nor melanoma cells were observed.
Immunohistochemical findings
The antibodies for immunohistochemistry are listed in
Table 1. An age-matched normal human retina and rela-
tively normal areas of the paraneoplastic vitelliform ret-
inopathy case were compared. In normal eye, different
types of retinal bipolar cells in the INL are stained posi-
tively with protein kinase C alpha (PKCα, Figure 2A) or
calbindin, a calcium binding protein (Figure 2B); how-
ever, the nuclei of these labeled bipolar cells were tightly
compact in this case. The thickness of the OPL was
greatly reduced (nearly 1/3 thickness of OPL in the
Figure 2 Photomicrograph of immunostaining in normal retina
and relatively intact areas of the paraneoplastic vitelliform
retinopathy case. (A) Protein kinase C alpha labeled bipolar cells
are tightly packed with blurred dendritic structures (arrows) and
condensed outer plexiform layer (OPL). (B) Calbindin positive bipolar
cells (arrows) are slightly packed with thinned and reduced OPL. (C)
Transient receptor potential M1 labeled ON bipolar cell dendritic tips
(arrows) had blurred structures and loss of puncta that appears in
normal human retina (Avidin-biotin-complex immunohistochemistry,
original magnification, ×200, scale bar, 50 μm).
Figure 1 Photomicrograph of retinal lesions in a case of
paraneoplastic vitelliform retinopathy. (A) Early-stage retinal
lesions with focal edema and splitting in the inner nuclear layer (INL,
short arrows) and outer nuclear layer (ONL, long arrows); mild
atrophy of outer plexiform layer (OPL) is also visible (asterisk). (B)
Late-stage retinal lesions with severe atrophy/loss of OPL (asterisks);
the lesion extends from INL (short arrows) and OPL (asterisks)
toward ONL (long arrows) regions (Hematoxylin and eosin, original
magnification, ×200, scale bar, 50 μm).
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appeared blurred (Figure 2A). TRPM1 staining demon-
strated a specific loss of puncta in the OPL of this case;
in contrast, the TRPM1-labeled dendritic tips of ON bi-
polar cells in normal eye are distinct and well defined,
located near the INL in the OPL (Figure 2C). The
immunoreactivities were similar in both eyes. There
were many metastatic melanoma cells infiltrated the
lung (Figure 3A), and these malignant cells were also
stained positively with TPRM1 antibody (Figure 3B).
TEM findings
TEM showed abnormal cellular structures in the INL
and OPL of the retina. The INL was characterized with
cytoplasmic degeneration and cellular disintegration at
different stages (Figure 4). The nuclei contained
chromosomal fragmentation. Many cells in the INL con-
tained damaged mitochondria, numerous lysosomal and
autophagous bodies in their cytoplasm (Figure 4 &
inset). Abundant empty vacuoles, disintegrated mito-
chondria, fragmented rough endoplasmic reticulum,
prominent glial filaments, and many apoptotic bodies
were admixed with the deteriorated synapses in the
OPL.Table 1 Cellular markers used in the study
Antibody Size Immunoreactivity
PKCα 82 kDa Rod bipolar cell, DB4 ON bipolar cell
Calbindin 28 kDa DB3 OFF bipolar cell
TRPM1 182 kDa ON bipolar dendrite, melanocyte
PKC= protein kinase C; DB=diffuse bipolar cells; TRPM1=transient receptor
potential M1.Discussion
Our study provides direct morphological evidence that
the retinal bipolar cells are damaged in paraneoplastic
vitelliform retinopathy. Importantly, TRPM1 is identified
as a target of anti-bipolar antibody produced in this pa-
tient with paraneoplastic vitelliform retinopathy. TRPM1
channels on the ON bipolar dendritic tips in the OPL
were specifically targeted and TRPM1 antigens were also
detected in the metastatic melanoma cells in the lung.
Additionally, the ultrastructures of the bipolar nuclei
and synapses were damaged.
In addition to previously reported serum autoanti-
bodies, including IRBP, CAII, and bestrophin in patients
with paraneoplastic vitelliform retinopathy [10,13,14],
peroxiredoxin 3 (PRDX3) is identified as a new putative
antigen in RPE attacked by autoantibodies in a melan-
oma patient with paraneoplastic vitelliform maculopathy
[12]. It is hypothesized that the paraneoplastic auto-
immune reaction against this 26-kDa PRDX3 may be a
cause of paraneoplastic vitelliform retinopathy. However,
our patient’s serum was only detected two retinal auto-
antibodies against a 30-kDa protein (CAII) and an un-
known 35-kDa RPE protein by Western blot [16].
Figure 3 Photomicrograph of immunostaining in metastatic lung melanoma of a case with paraneoplastic vitelliform retinopathy. (A)
Metastatic melanoma cells infiltrate in the lung tissue (Hematoxylin and eosin, original magnification, ×400). (B) Transient receptor potential M1
labeled melanocytes are observed in the lung metastasis (Avidin-biotin-complex immunohistochemistry, original magnification, ×400, scale bar,
100 μm).
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several types of neurons. Bipolar cells in the INL are the
second-order neurons that play an essential role in visual
signal transduction. Other cells in the INL that are
related to bipolar cell signaling processing include ama-
crine, horizontal, and Müller cells. Their detailed func-
tion and cell markers are summarized in Table 2.
Through complicated synaptic interactions, bipolar cell
dendrites receive information from the photoreceptors
and horizontal cells and transmit these signals to the
ganglion and amacrine cells. Based on the two types of
photoreceptors (rods and cones) that they connect to,
bipolar cells are divided into one rod subtype (ON type)Figure 4 Transmission electron microscopy photomicrograph
of inner nuclear layer of retina in paraneoplastic vitelliform
retinopathy. The degenerated cells are at various stages of
disintegration and most of their cytoplasmic organelles are absent.
The mitochondria were degenerate and only their outer membranes
were visible (arrows, original magnification, ×8000, scale bar, 2 μm).
There were numerous lysosomal and autophagous bodies (Figure 4
inset, original magnification, ×25000) within the cells.and 8 cone subtypes (ON and OFF types). Light hyper-
polarizes photoreceptors and reduces glutamate release
from photoreceptors. The reduced glutamate levels
depolarize ON bipolar cells and hyperpolarizes OFF bi-
polar cells. The opposite responses of bipolar cells are
mediated by different glutamate receptors (GluRs)
expressed on ON (metabotropic GluR, mGluR6) and
OFF (ionotropic GluRs) bipolar dendrites [31,32].
Responses of photoreceptors and bipolar cells are
reflected in ERG a- and b- waves, respectively. Unlike
ionotropic GluRs on OFF bipolar cells, which are ion-
permeable channels themselves, mGluR6 receptors on
ON bipolar cells are G-protein coupled receptors that
are separated from the channels that they gate [33]. Re-
cently, TRPM1 has been identified to be the cation chan-
nel that is downstream to the mGluR6 cascade of ON
bipolar cells [22,24].
Recently, TRPM1 is identified as a suspected target of
the autoantibodies produced in melanoma patients with
MAR [30]. Dhingra et al. [29] demonstrate that sera of
melanoma patients with PR specifically recognized
TRPM1 in mouse bipolar cells. Up to date, no TRPM1 ab-
normality has been illustrated in the human retina of
paraneoplastic vitelliform retinopathy. Although the clin-
ical findings of PR patients with serum anti-TPRM1 auto-
antibody have reported in the literature (CAR and MAR
patients) [29,30], the pathological mechanism of all these
PR entities is through the common identified TRPM1
channel. Additional unknown mechanisms may play a role
in determining the phenotypes of PR patients. In this
study, we illustrate that TRPM1 channels are diffusely
damaged and TRPM1 antigen is also expressed on the
metastatic lung melanoma cells. Although downregulation
or loss of TRPM1 expression has been reported in melan-
oma metastasis [18], this study cannot compare TRRM1
expression levels between original cutaneous melanoma
and lung metastasis in this case due to lack of original
melanoma specimens. However, our findings strongly sup-
port that anti-TRPM1 autoantibody is involved in the
Table 2 Neuron cells in the inner nuclear layer and their functions and markers
Cell type Function Cell marker
Bipolar Responsible for signals transmitting from photoreceptors to
retinal ganglion cells; divided into ON and OFF bipolar cells
according to their responses to visual stimuli: light stimuli
increase the conductance of ON bipolar cells but decrease
that in OFF bipolar cell
ON bipolar: PKCα (rod, DB4), CD15 (DB6), Islet-1, Glycine, Goα [34];
OFF bipolar: Recoverin, Glutamate transporter-1(DB2), PKCβ,
Calbindin (DB3) [34]; ON and OFF bipolar: CaB5 [34]
Amacrine Responsible for modulation of signal reaching ganglion
cells; affecting orientation selectivity, light–dark effect and
color discrimination
Syntaxin [35], Dab1, AP2α [36], Pax6 [37],
Horizontal Having an integrative role in retinal processing and release
inhibitory neurotransmitters; providing feedback for the
photoreceptors
Parvalbumin [38]
Müller Forming architectural support structures in the retina;
involved in protein synthesis, intracellular transport and
secretion; helping nourish and maintain the outer neuroretina
Glutamine synthetase [39]
PKC=protein kinase C; DB= diffuse bipolar cells; CaB5=calcium-binding protein 5; Dab1=Disabled-1; AP2α=activator Protein 2 alpha; Pax6=paired box.
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atypical MAR. ERG of Trpm1 deficient mice has a normal
a-wave, but no b-wave, indicating a loss of bipolar cell re-
sponse [24]. The damaged TRPM1 channel, either before
or after ON bipolar cell damage, could cause abnormal
light signal transduction, which consequently affects night
vision and ERG b-wave. In this case, lesions were also
found from the INL and OPL extending to the ONL that
might cause abnormal ERG a-wave. However, whether the
ONL changes are primary or secondary events remains to
be resolved.Conclusions
Both immunohistochemistry and TEM showed specific
damages in bipolar cells and TRPM1 cation channel on
the ON bipolar dendritic tips. The immunohistochem-
ical data provide evidence of autoantibodies against the
TRPM1 cation channel on retinal ON bipolar cells and
metastatic melanoma cells in paraneoplastic vitelliform
retinopathy.Consent
Written informed consent was obtained from the
patient’s family for publication of this Case report and
any accompanying images. A copy of the written consent
is available for review by the Series Editor of this
journal.
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